Madrigal Pharma (MDGL) Confirms FDA Approval of Rezdiffra for Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Go back to Madrigal Pharma (MDGL) Confirms FDA Approval of Rezdiffra for Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis| (NASDAQ: MDGL) | Delayed: 512.88 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $512.88 | 52 Week High | $18.24 | |||
| Open | $512.88 | 52 Week Low | $6.60 | |||
| Day High | $512.88 | P/E | N/A | |||
| Day Low | $512.88 | EPS | $0.00 | |||
| Volume | 4 | |||||
